3 Patients Already Dosed In TC BioPharm’s Phase 2b Trial Of A Cutting Edge T Cell Therapy For Hard-to-Treat Cancers
This week, TC BioPharm Holdings PLC TCBP , a clinical-stage biotech working on cutting-edge immunotherapies for some of the most difficult-to-treat cancers, announced that...